Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jul;74(2):274–279. doi: 10.1038/bjc.1996.351

Transforming growth factor beta 1 (TGF-beta 1) produced in tumour tissue after chemotherapy acts as a lymphokine-activated killer attractant.

Y Kuramitsu 1, M Nishibe 1, M Kobayashi 1, Y Togashi 1, L Yuan 1, M Takizawa 1, F Okada 1, M Hosokawa 1
PMCID: PMC2074585  PMID: 8688335

Abstract

Using an under agarose migration (UAM) assay, we studied lymphokine-activated killer (LAK)-attractant activity in cultured conditioned medium of tumour tissues after chemotherapy as a possible mechanism of enhanced LAK cell accumulation into tumour tissues after chemotherapy. BMT-11 is a fibrosarcoma developed in C57BL/6 mice. The conditioned medium of BMT-11 tumour tissues obtained from mice treated with various anti-cancer drugs had chemotactic activity for LAK cells (LAK-attractant activity). mRNA expression of interleukin (IL)-1 alpha, IL-6, IL-8, interferon (IFN)-gamma, and tumour necrosis factor (TNF)-alpha was observed in untreated tumour tissues, which were not enhanced by cyclophosphamide treatment. mRNA expression of TGF-beta 1 was not detected in untreated tumour tissues by reverse transcription-polymerase chain reaction (RT-PCR), but was detected in tumour tissues treated with cyclophosphamide. Recombinant human TGF-beta 1 showed LAK-attractant activity at a concentration of 0.1 ng ml-1 and 1 ng ml-1, whereas fresh splenocytes were not attracted by TGF-beta 1. Anti-TGF-beta 1 antibody inhibited LAK-attractant activity in the conditioned medium of tumour tissues treated with cyclophosphamide to approximately 35% that of control at 100 micrograms ml-1. These findings indicate that TGF-beta 1 produced in the tumour tissues of mice treated with anti-cancer drugs could be a LAK attractant. By a 4 h 51Cr release assay of natural killer cell-resistant BMT-11 tumour cells, we observed that TGF-beta 1 at a concentration from 0.01 ng ml-1 to 10 ng ml-1 did not inhibit LAK activity in an effector phase. Taken together, we suggest that TGF-beta 1 produced in tumour tissues after chemotherapy participates in gathering transferred LAK cells and contributes to the therapeutic effects of transferred LAK cells.

Full text

PDF
274

Images in this article

276Figure 1
on p.276
277Figure 2
on p.277

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams D. H., Hathaway M., Shaw J., Burnett D., Elias E., Strain A. J. Transforming growth factor-beta induces human T lymphocyte migration in vitro. J Immunol. 1991 Jul 15;147(2):609–612. [PubMed] [Google Scholar]
  2. Ames I. H., Gagne G. M., Garcia A. M., John P. A., Scatorchia G. M., Tomar R. H., McAfee J. G. Preferential homing of tumor-infiltrating lymphocytes in tumor-bearing mice. Cancer Immunol Immunother. 1989;29(2):93–100. doi: 10.1007/BF00199283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chenoweth D. E., Rowe J. G., Hugli T. E. A modified method for chemotaxis under agarose. J Immunol Methods. 1979;25(4):337–353. doi: 10.1016/0022-1759(79)90026-7. [DOI] [PubMed] [Google Scholar]
  4. Chiu C. P., Moulds C., Coffman R. L., Rennick D., Lee F. Multiple biological activities are expressed by a mouse interleukin 6 cDNA clone isolated from bone marrow stromal cells. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7099–7103. doi: 10.1073/pnas.85.19.7099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Delens N., Torreele E., Savelkool H., De Baetselier P., Bouwens L. Tumor-derived transforming growth factor-beta 1 and interleukin-6 are chemotactic for lymphokine-activated killer cells. Int J Cancer. 1994 Jun 1;57(5):696–700. doi: 10.1002/ijc.2910570515. [DOI] [PubMed] [Google Scholar]
  6. Felgar R. E., Hiserodt J. C. In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats. Cell Immunol. 1990 Sep;129(2):288–298. doi: 10.1016/0008-8749(90)90205-6. [DOI] [PubMed] [Google Scholar]
  7. Futami H., Pilaro A. M., Gruys M. E., Back T. C., Young H. A., Wiltrout R. H. In vivo distribution and cytokine gene expression by enriched mouse LAK effector cells. Biotherapy. 1991;3(3):219–232. doi: 10.1007/BF02171685. [DOI] [PubMed] [Google Scholar]
  8. Gray P. W., Goeddel D. V. Cloning and expression of murine immune interferon cDNA. Proc Natl Acad Sci U S A. 1983 Oct;80(19):5842–5846. doi: 10.1073/pnas.80.19.5842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 1;155(6):1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hosokawa M., Sawamura Y., Morikage T., Okada F., Xu Z. Y., Morikawa K., Itoh K., Kobayashi H. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide. Cancer Immunol Immunother. 1988;26(3):250–256. doi: 10.1007/BF00199937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hosokawa M., Wakizaka Y., Kuramitsu Y., Micallef M., Togashi Y., Kobayashi H. Augmented accumulation of transferred lymphokine-activated killer (LAK) cells at murine tumor sites through production of LAK-attractant facilitated by chemotherapy. Tohoku J Exp Med. 1992 Oct;168(2):413–416. doi: 10.1620/tjem.168.413. [DOI] [PubMed] [Google Scholar]
  12. Ishikawa M., Okada F., Hamada J., Hosokawa M., Kobayashi H. Changes in the tumorigenic and metastatic properties of tumor cells treated with quercetin or 5-azacytidine. Int J Cancer. 1987 Mar 15;39(3):338–342. doi: 10.1002/ijc.2910390312. [DOI] [PubMed] [Google Scholar]
  13. Kawata A., Hosokawa M., Sawamura Y., Ito K., Une Y., Shibata T., Uchino J., Kobayashi H. Modification of lymphokine-activated killer cell accumulation into tumor sites by chemotherapy, local irradiation, or splenectomy. Mol Biother. 1990 Dec;2(4):221–227. [PubMed] [Google Scholar]
  14. Lomedico P. T., Gubler U., Hellmann C. P., Dukovich M., Giri J. G., Pan Y. C., Collier K., Semionow R., Chua A. O., Mizel S. B. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. 1984 Nov 29-Dec 5Nature. 312(5993):458–462. doi: 10.1038/312458a0. [DOI] [PubMed] [Google Scholar]
  15. Lotze M. T., Line B. R., Mathisen D. J., Rosenberg S. A. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol. 1980 Oct;125(4):1487–1493. [PubMed] [Google Scholar]
  16. Lucas C., Fendly B. M., Mukku V. R., Wong W. L., Palladino M. A. Generation of antibodies and assays for transforming growth factor beta. Methods Enzymol. 1991;198:303–316. doi: 10.1016/0076-6879(91)98031-z. [DOI] [PubMed] [Google Scholar]
  17. Maghazachi A. A., Herberman R. B., Vujanovic N. L., Hiserodt J. C. In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells. Cell Immunol. 1988 Aug;115(1):179–194. doi: 10.1016/0008-8749(88)90172-4. [DOI] [PubMed] [Google Scholar]
  18. Miossec P., Cavender D., Ziff M. Interleukin 1 derived from human endothelial cells enhances the binding and chemotactic step of T lymphocyte emigration. Clin Exp Immunol. 1988 Aug;73(2):250–254. [PMC free article] [PubMed] [Google Scholar]
  19. Natuk R. J., Welsh R. M. Chemotactic effect of human recombinant interleukin 2 on mouse activated large granular lymphocytes. J Immunol. 1987 Oct 15;139(8):2737–2743. [PubMed] [Google Scholar]
  20. Nelson R. D., Quie P. G., Simmons R. L. Chemotaxis under agarose: a new and simple method for measuring chemotaxis and spontaneous migration of human polymorphonuclear leukocytes and monocytes. J Immunol. 1975 Dec;115(6):1650–1656. [PubMed] [Google Scholar]
  21. Nitta T., Nakata M., Yagita H., Okumura K. Interleukin-2 activated T cells (T-LAK) express CD16 antigen and are triggered to target cell lysis by bispecific antibody. Immunol Lett. 1991 Apr;28(1):31–37. doi: 10.1016/0165-2478(91)90124-s. [DOI] [PubMed] [Google Scholar]
  22. Nitta T., Sato K., Yagita H., Okumura K., Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet. 1990 Feb 17;335(8686):368–371. doi: 10.1016/0140-6736(90)90205-j. [DOI] [PubMed] [Google Scholar]
  23. Ohmori Y., Hamilton T. A. A macrophage LPS-inducible early gene encodes the murine homologue of IP-10. Biochem Biophys Res Commun. 1990 May 16;168(3):1261–1267. doi: 10.1016/0006-291x(90)91164-n. [DOI] [PubMed] [Google Scholar]
  24. Okada F., Hosokawa M., Hasegawa J., Ishikawa M., Chiba I., Nakamura Y., Kobayashi H. Regression mechanisms of mouse fibrosarcoma cells after in vitro exposure to quercetin: diminution of tumorigenicity with a corresponding decrease in the production of prostaglandin E2. Cancer Immunol Immunother. 1990;31(6):358–364. doi: 10.1007/BF01741407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Pennica D., Hayflick J. S., Bringman T. S., Palladino M. A., Goeddel D. V. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci U S A. 1985 Sep;82(18):6060–6064. doi: 10.1073/pnas.82.18.6060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pockaj B. A., Sherry R. M., Wei J. P., Yannelli J. R., Carter C. S., Leitman S. F., Carasquillo J. A., Steinberg S. M., Rosenberg S. A., Yang J. C. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer. 1994 Mar 15;73(6):1731–1737. doi: 10.1002/1097-0142(19940315)73:6<1731::aid-cncr2820730630>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  27. Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485–1492. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  28. Rugo H. S., O'Hanley P., Bishop A. G., Pearce M. K., Abrams J. S., Howard M., O'Garra A. Local cytokine production in a murine model of Escherichia coli pyelonephritis. J Clin Invest. 1992 Mar;89(3):1032–1039. doi: 10.1172/JCI115644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Tada T., Ohzeki S., Utsumi K., Takiuchi H., Muramatsu M., Li X. F., Shimizu J., Fujiwara H., Hamaoka T. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol. 1991 Feb 1;146(3):1077–1082. [PubMed] [Google Scholar]
  30. Tokunaga K., Taniguchi H., Yoda K., Shimizu M., Sakiyama S. Nucleotide sequence of a full-length cDNA for mouse cytoskeletal beta-actin mRNA. Nucleic Acids Res. 1986 Mar 25;14(6):2829–2829. doi: 10.1093/nar/14.6.2829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Wahl S. M., Allen J. B., Weeks B. S., Wong H. L., Klotman P. E. Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4577–4581. doi: 10.1073/pnas.90.10.4577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Wahl S. M., McCartney-Francis N., Mergenhagen S. E. Inflammatory and immunomodulatory roles of TGF-beta. Immunol Today. 1989 Aug;10(8):258–261. doi: 10.1016/0167-5699(89)90136-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES